![]() |
Volumn 62, Issue 5, 2016, Pages 663-665
|
B-type natriuretic peptide testing in the era of neprilysin inhibition: Are the winds of change blowing?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ADRENOMEDULLIN;
ANGIOTENSIN RECEPTOR ANTAGONIST;
ATRIAL NATRIURETIC FACTOR;
BIOLOGICAL MARKER;
BRADYKININ;
BRAIN NATRIURETIC PEPTIDE;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
ENALAPRIL;
MEMBRANE METALLOENDOPEPTIDASE;
NATRIURETIC PEPTIDE TYPE C;
SACUBITRIL PLUS VALSARTAN;
AMINOBUTYRIC ACID DERIVATIVE;
PEPTIDE FRAGMENT;
CARDIOVASCULAR DISEASE;
CROSS REACTION;
GOLD STANDARD;
HEART FAILURE;
HEART LEFT VENTRICLE EJECTION FRACTION;
HEART VENTRICLE REMODELING;
HOSPITALIZATION;
HUMAN;
IMMUNOASSAY;
IN VITRO STUDY;
MASS SPECTROMETRY;
MORTALITY;
PATIENT CARE;
PRACTICE GUIDELINE;
RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;
REVIEW;
SODIUM RETENTION;
VASOCONSTRICTION;
AMINOBUTYRATES;
ATRIAL NATRIURETIC FACTOR;
HEART FAILURE;
NATRIURETIC PEPTIDE, BRAIN;
NEPRILYSIN;
PEPTIDE FRAGMENTS;
|
EID: 84964854198
PISSN: 00099147
EISSN: 15308561
Source Type: Journal
DOI: 10.1373/clinchem.2016.255455 Document Type: Review |
Times cited : (7)
|
References (6)
|